Instil Bio Inc. (TIL) Appoints John Maraganore to its Board

Instil Bio, Inc. (“Instil”) (NASDAQ: TIL), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies, today announced the addition of John Maraganore, Ph.D., to the Board of Directors of Axion Bio, Inc., Instil’s wholly-owned subsidiary dedicated to the development of AXN-2510 (“’2510”), a potentially best-in-class PD-L1xVEGF bispecific antibody for solid tumors prioritizing front-line non-small cell lung cancer (NSCLC).

“John’s appointment reflects our commitment to assembling world-class leadership to maximize the value of the ‘2510 program for patients and shareholders, and we have benefited greatly from his strategic advice over the past year,” said Bronson Crouch, CEO of Instil. “His deep industry experience and strategic insight will be critical as we continue to advance our PD-L1xVEGF bispecific, which we believe has the potential to redefine the standard of care for patients with solid tumors.”

“I am thrilled to continue to partner with the team at Instil to support the further development of ‘2510,” said Dr. Maraganore. “This program has a strong scientific rationale, early signs of robust activity, and clear differentiation from others in our therapeutic area. As we approach the completion of enrollment of ImmuneOnco’s Phase 2 trial of ‘2510 in combination with chemotherapy in patients with first-line NSCLC this summer, I believe ‘2510 is in a highly strategic position with its early attractive safety and efficacy profile. My goal is to aid Instil in navigating to its next stage of growth during this exciting time."

Dr. John Maraganore is a seasoned biotechnology executive with over 30 years of experience in building and leading innovative life sciences companies, with a deep focus on translating breakthrough science into transformative medicines. He was the founding CEO of Alnylam Pharmaceuticals (Nasdaq: ALNY), where he led the company from its inception in 2002 through nearly two decades of growth as it recently crossed $40 billion in market capitalization. Dr. Maraganore’s passion and hard work advanced RNA interference (RNAi) from a nascent platform into a validated therapeutic modality, thus bringing multiple first-in-class RNAi medicines to market. He currently serves on the boards of several public and private biotech companies focused on areas such as oncology, immunology, and precision medicine, and advises leading investment firms in the life sciences sector. His breadth of experience across drug discovery, clinical development, and strategic partnering makes him an invaluable partner in guiding the advancement of next-generation cancer therapies.

You May Also Be Interested In

• FutureFuel director Paul Manheim to retire from board in 2026
• Spyre Therapeutics (SYRE) files mixed shelf
• Corporación América Airports signs Brasilia concession amendment